Please ensure Javascript is enabled for purposes of website accessibility

Why Exact Sciences Stock Soared 10% Today

By Todd Campbell - May 24, 2016 at 9:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The colon cancer detection company's shares recovered some losses from earlier this month.

Image source: Exact Sciences.

What: After losing 23% of their value this month through May 20, shares of Exact Sciences (EXAS -5.88%) shares have rallied 14%, including a 10.2% gain today.

EXAS Chart

EXAS data by YCharts

So what: Despite reporting revenue and profit in early May that outpaced expectations, the company's sales pace and lack of profitability continue to disappoint investors.

In the first quarter, management delivered revenue growth of 248% as prescription volume for its colon cancer detection kit skyrocketed. That would normally be a good thing, but management helped drive that demand by significantly increasing its spending, and that's got investors wondering when (or if) this company can turn a profit.

Exact Sciences' spending on cost of goods sold climbed by $4.8 million versus last year in the first quarter, and spending on advertising jumped by $9.2 million when compared with a year ago. Add those two figures together and you find that management bumped up spending by $14 million, only to see sales improve by $10.6 million.

Because of the increase in its costs, Exact Sciences quarterly loss grew to $47.5 million, or $0.49 per share, from $35.8 million, or $0.40 per share, in the same quarter a year ago.

Now what: Following the sell-off earlier this month, investors appear to be bargain-hunting.

The population of seniors who could benefit from the Cologuard kit is undeniably big and growing as more baby boomers move into their 60s. If Exact Sciences advertising can help establish its test as the go-to test among seniors, then it stands that the company's sales could climb significantly. Theoretically, the company could rein in spending once the number of kits reaches a tipping point, boosting margin and getting the company into the black.

However, investors might want to temper their enthusiasm. It may be years before the company begins selling enough tests to be at that magic tipping point. If so, then investing in Exact Sciences may not pay off until next decade. Given the risk of mounting losses, a patient approach to this company is necessary.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exact Sciences Corporation Stock Quote
Exact Sciences Corporation
$41.51 (-5.88%) $-2.60

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.